|
|
News Breaks | | | | November 15, 2012 | | 07:22 EDT |  | GILD | Gilead's single tablet Stribild shows positive results in two HIV studies
Gilead announced two-year results from two pivotal Phase 3 studies evaluating the company’s newest single tablet HIV regimen, StribildTM, among treatment-naïve patients with HIV-1 infection. Data show that Stribild was non-inferior after two years of treatment to two standard of care HIV regimens, Atripla in Study 102 and a protease-based regimen of ritonavir-boosted atazanavir plus Truvada in Study 103. The regimen was approved by the FDA on August 27 for use by treatment-naïve HIV-positive adults based on 48-week results from Studies 102 and 103. A marketing application for Stribild is currently under review in the European Union. | |
|
News For GILD From The Last 14 Days Check below for free stories on GILD the last two weeks. |
|
|
| There are no results for GILD |
|
|
|
|
|
|
